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ABSTRACT
Existing therapies for multi-drug resistant
tuberculosis (MDR-TB) have substantial
limitations, in terms of their effectiveness,
side-effect profile, and complexity of
administration. Bedaquiline is a novel
diarylquinoline antibiotic that has recently
been investigated as an adjunct to existing
therapies for MDR-TB. Currently, limited
clinical data are available to evaluate the
drug’s safety and effectiveness. In two small
randomized-controlled clinical studies,
bedaquiline given for 8 or 24 weeks has been
shown to improve surrogate microbiological
markers of treatment response, but trials have
not yet evaluated its impact on clinical failure
and relapse. Safety concerns include an
increased mortality in the bedaquiline arm of
one study, an increased incidence of QT
segment prolongation on electrocardiogram,
and hepatotoxicity. Until further research data
are available, the use of bedaquiline should be
confined to settings where carefully selected
patients can be closely monitored.
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Tuberculosis (TB) is an airborne infectious
disease caused by M. tuberculosis, with an
incidence of almost nine million cases each
year worldwide [1]. Standard treatment
regimens are highly effective for patients with
drug-sensitive disease, although they require a
combination of four anti-TB drugs for
2 months, followed by two drugs for an
additional 4–6 months [2]. However, treatment
outcomes are substantially worse for patients
with disease that is resistant to isoniazid and
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rifampin—the two key drugs of the standard
regimens [3].
Multi-drug-resistant (MDR)-TB is caused by
bacilli, which are resistant at least to rifampicin
and isoniazid [1], and occurs in 3.7% of all
newly diagnosed cases and 20% of previously
treated cases [1], although in some settings the
prevalence is much higher. Treatment of MDR-
TB is substantially more complex, more costly,
and less effective than standard therapy,
typically requiring the use of at least six anti-
TB drugs, including an injectable agent and a
total treatment duration of more than
18 months [4]. Extensively drug-resistant
(XDR)-TB, defined as MDR-TB with resistance
to a fluoroquinolone and a second-line
injectable antibiotic, requires even more
lengthy and complex treatment. Drugs used to
treat both MDR- and XDR-TB are often poorly
tolerated and associated with high rates of
adverse events. Treatment is successful in only
50–80% of cases of MDR-TB [5–7], and less than
50% of cases for XDR-TB [8]. In light of the
limitations of existing therapy, the Global Plan
to Stop TB has highlighted the importance of
developing additional drug regimens that are
effective against drug-resistant disease [9].
Bedaquiline (previously known as TMC207)
is a novel member of the diarylquinoline class
of anti-TB drugs. Following promising results in
a number of pre-clinical and clinical studies, the
drug was approved in 2012 by the US Food and
Drug Administration (FDA) for use in the
treatment of pulmonary MDR-TB [10]. An
expert group convened by the World Health
Organization has also released interim policy
recommendations regarding the use of
bedaquiline as a part of treatment for
pulmonary MDR-TB [11]. However, concerns
have been raised about the drug’s effectiveness
and safety [12, 13].
This review evaluates the available clinical
evidence for the use of bedaquiline to treat
drug-resistant TB.
METHODS
A literature search was performed using
PubMed, applying the search terms
‘‘bedaquiline’’ or ‘‘TMC207’’ and ‘‘tuberculosis’’,
for studies published up to April 1, 2013. The
full-text of articles was reviewed. The website of
the US FDA was also searched for available data
about bedaquiline, and data from publically
available reports and submissions were included
in this review. For comparisons between
bedaquiline and placebo groups, if P values
were not stated in the publication then they
were calculated using Pearson’s v2 test or
Fisher’s exact test. For studies where follow-up
data were incomplete, outcomes were included
up to the stated cut-off reporting dates.
MECHANISM OF ACTION
Bedaquiline is a diarylquinoline compound that
specifically inhibits the proton pump of
mycobacterial adenosine triphosphate (ATP)
synthase, which is essential for mycobacterial
energy generation [14, 15]. The drug is
structurally and mechanistically different than
fluoroquinolone antibiotics, and other related
quinoline classes of drugs. This means that
antibiotic resistance to fluoroquinolones, which
are a part of standard treatment of MDR-TB,
does not also confer resistance to bedaquiline
[14].
Bedaquiline has bactericidal activity in vitro
against M. tuberculosis as well as other
mycobacterial species [14]. It inhibits both
actively replicating and non-replicating
mycobacteria, with one study showing
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inhibition of dormant cells in latent TB
infection at a low concentration [16].
Mycobacterial susceptibility to the drug is
unaltered in the presence of resistance to other
anti-TB drugs, including isoniazid, rifampicin,





Bedaquiline is given orally, reaching peak
concentration 5 h after administration [14].
Eating food at the same time as taking the
drug doubles its bioavailability compared with
taking it when fasting [17]. Consequently,
bedaquiline should be given with food.
The active drug undergoes oxidation
primarily in the liver, by cytochrome P3A4
(CYP3A4), to a less active metabolite N-
monodesmethyl (M2) that has a three- to six-
fold lower antimicrobial effect than bedaquiline
[17]. Hence, co-administration of drugs that
potentiate CYP3A4, such as rifampicin, is likely
to reduce the plasma concentrations of the
bedaquiline and potentially reduce its
effectiveness. Conversely, drugs that inhibit
these enzymes, such as protease inhibitors,
macrolide antibiotics, and azole antifungals,
may increase systemic concentrations and the
likelihood of adverse events. The primary
metabolite of bedaquiline, M2, is removed
mainly in the stool, with only 1–4% removed
in the urine [15]. Although patients with
advanced renal impairment were excluded
from Phase 1 and 2 studies, mild-to-moderate
renal impairment (median creatinine clearance
108 mL/min, range 39.8–227 mL/min) did not
affect the drug’s pharmacokinetics [17].
Bedaquiline has a multi-phasic distribution
and an effective half-life of 24 h, which is
substantially longer than most other anti-
tuberculosis drugs [14, 15].
Importantly, the drug has a very long
terminal elimination half-life of 5.5 months
[17], owing to a combination of a long plasma
half-life, high tissue penetration (particularly
the organs affected by TB), and long half-life in
tissues [14]. While this means that less frequent
dosing may be feasible, adverse events may also
be prolonged after drug cessation.
The initial safety studies of bedaquiline
found that its pharmacokinetics was not
influenced by age, sex, body weight, and
human immunodeficiency virus (HIV)-co-
infection in the absence of anti-retroviral
treatment [17]. In these studies, subjects of
black ethnicity had lower concentrations of
bedaquiline than other races. Of note, in light
of this finding, bedaquiline did not improve
treatment outcomes in one sub-group of people
of African ancestry in a recent clinical trial [17].
The pharmacokinetics of bedaquiline has
only been studied in adults from 18–65 years,
and not yet in pediatric or elderly populations.
Phase 2 studies suggest that there is no need to
adjust dose for patients with hepatic or renal
impairment, although caution should be used
in patients with severe renal or hepatic disease
[18].
DOSING AND ADMINISTRATION
Bedaquiline is currently available as an oral,
uncoated, immediate-release tablet which
contains 100 mg of bedaquiline-free base [15].
The recommended dose, as a part of
combination therapy for pulmonary MDR-TB,
is 400 mg daily for 2 weeks, followed by 200 mg
three times per week. Regimens used in
published studies have given the drug as a part
Infect Dis Ther (2013) 2:123–144 125
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of MDR-TB therapy for up to 24 weeks in total
[15, 18, 19].
The published pre-clinical and Phase 1
clinical studies of bedaquiline are summarized
in Tables 1 [14–16, 20–54] and 2 [15, 55–60].
CLINICAL EVIDENCE FOR THE
EFFICACY OF BEDAQUILINE
IN MDR-TB
The available data evaluating efficacy of
bedaquiline are limited to one published Phase
2 clinical study of 47 patients [14, 18, 19]. Data
from two other Phase 2 studies have been made
available by the manufacturer in its public
submission to the US FDA [15, 17]. In these
trials, summarized in Figs. 1 [18, 19], 2 [17], and
3 [17], the drug was given for a maximum of
24 weeks. Time to culture conversion at 8, 24,
72, and 104 weeks was the reported end-points.
The data from these studies describing the
impact of bedaquiline upon clinical end
points, such as the rate of cure at 104 weeks,
have not yet been published.
The First Phase 2 Study of Bedaquiline
In the one randomized controlled trial on
efficacy for which published data are available
[14, 18, 19], patients aged 18–65 years with
MDR-TB from six centers in South Africa were
enrolled. In total, 47 patients were randomized
to either bedaquiline or a placebo for 8 weeks
(Table 3) [17–19]. Both groups also took an
optimized background regimen (OBR)
comprising standard treatment for MDR-TB,
which was considered to be most appropriate
by treating clinicians in that setting. Treatment
outcomes have been published in three separate
reports - for 8 weeks [18], 24 weeks [19], and
104 weeks [19] of follow-up.
The primary end point of this study, time to
culture conversion at 8 weeks, was significantly
shorter for patients taking bedaquiline than for
those taking an OBR with placebo (hazard ratio
Table 1 Summary of pre-clinical studies of bedaquiline
Subject of study References
Chemical synthesis [20]








animal studies (such as
mice studies)
[15, 32]




against M. tuberculosis in
animal studies
[14, 15, 33–43]





[14, 16, 49, 50]
Bactericidal effect against
other mycobacteria
[51] (M. avium), [52] and
[53] (M. leprae) [16],
(M. smegmatis), [54] (non-
tuberculous mycobacteria)
Table 2 Summary of Phase 1 clinical studies of
bedaquiline
Subject of study References
Pharmacokinetics/pharmacodynamics [15, 55]
Safety and tolerability [55]
Dose ranging [56]
Pharmacokinetic drug interactions [57]
Modeling study [58]
Bactericidal effect [55, 59, 60]
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[HR] 11.8 [2.3, 61.3], P = 0.0034), with
adjustment for cavitation and study center)
[18]. In addition, patients taking bedaquiline
plus OBR had significantly greater proportion of
culture conversion at 8 weeks compared to OBR
plus placebo (47.6% versus 8.7%, respectively).
Culture conversion at 24 weeks was also
significantly greater among patients taking
bedaquiline compared to OBR with placebo
(81.0% versus 65.2%) [19], and time to culture
conversion at 24 weeks was also shorter (HR 2.3,
95% CI 1.1, 4.7) [19]. When an intention to
treat analysis was performed for all subjects up
to 104 weeks, the rate of microbiological
conversion was not significantly different
between the bedaquiline group and placebo
(52.4% versus 47.8%, P = 0.76) [19]. This is due
in part to the high drop-out rates seen in both
Fig. 1 Summary of ﬁrst Phase 2 study. *Subjects were
excluded from the mITT analysis, as subjects did not meet
inclusion criteria despite being randomized. **Calculations
based upon mITT analysis. ***P values calculated using
uncorrected v2 statistic with data from the modiﬁed
intention to treat analysis. ****Culture results in discon-
tinuing patients reported for time of last available culture
[19]. Italicized P values were calculated from data in papers.
aContinuing patients: refers only to patients continuing
follow-up, excluding subjects withdrawing prior to stated
time points (8 weeks, 24 weeks, and 104 weeks). Source:
data from [18, 19]. BDQ bedaquiline, mITT modiﬁed
intent to treat, na not available, XDR-TB extensively drug-
resistant tuberculosis
Infect Dis Ther (2013) 2:123–144 127
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arms (44% drop-out in the bedaquiline group
and 54% in the placebo group).
The study was not powered to detect relapse,
although at the end of the study two members
of the bedaquiline group and four members of
the control group had experienced treatment
failure [17, 61].
The Second Phase 2 Study of Bedaquiline
Data from a second Phase 2 study of the clinical
effectiveness of bedaquiline (Study C208, Stage
2) have been presented in a public submission
to the US FDA, although the results have not yet
appeared in a peer-reviewed publication. This
Fig. 2 Summary of second Phase 2 study. *Excluded from
mITT analysis. Subject was excluded after being random-
ized, before receiving bedaquiline, based on an adverse
event. **Calculations based upon mITT analysis. ***A
subject was considered responder (missing = failure) if at
least 2 cultures from sputa collected at least 25 days apart
were MGIT culture negative (as well as all intermediate
cultures), this culture negativity was not followed by a
conﬁrmed positive MGIT culture (or a single positive
sputum result after which the subject completed the trial),
and the subject did not discontinue up to the time point
being analyzed. ****A subject was considered responder (no
overruling) if at least 2 cultures from sputa collected at least
25 days apart were MGIT culture negative (as well as all
intermediate cultures) and this culture negativity was not
followed by a conﬁrmed positive MGIT culture (or a single
positive sputum result after which the subject completed or
discontinued the trial) up to the time point being analyzed.
aContinuing patients: refers only to patients continuing
follow-up, excluding subjects withdrawing prior to stated
time points (24 weeks, 72 weeks, and 104 weeks). Source:
data from [17]. BDQ bedaquiline, DST Drug susceptibility
testing, MGIT Mycobacteria Growth Indicator Tube,
mITT modiﬁed intention to treat, Na not available
128 Infect Dis Ther (2013) 2:123–144
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study enrolled 161 patients with MDR-TB, at 15
study sites in eight countries [17]. Patients were
randomized either to 24 weeks of bedaquiline
with a five-drug OBR or the OBR plus placebo.
OBR was continued after stopping bedaquiline
or placebo. The primary end point was time to
sputum culture conversion at 24 weeks (Table 4)
[15, 17]. The two groups were comparable.
A modified intention to treat analysis
showed that culture conversion during the
first 24 weeks was faster in the group with
bedaquiline than the control group (83 days
versus 125 days, HR 2.44 [95% CI 1.57, 3.80],
P\0.0001) [17], but there was no significant
difference between the treatment groups in this
outcome at 72 weeks (P = 0.069) [17]. During
the 2-year follow-up, three patients in the
bedaquiline group and seven in the control
group experienced treatment failure.
Third Phase 2 Study of Bedaquiline
Preliminary results are also available from a
third, uncontrolled study of 233 patients
enrolled at 33 sites in Asia, South Africa,
Eastern Europe, and South America (Study
Fig. 3 Summary of third Phase 2 study data from [17].
BDQ bedaquiline, DS drug susceptible, mITT modiﬁed
intention to treat, TB tuberculosis. aContinuing patients:
refers only to patients continuing follow-up, excluding
subjects withdrawing prior to stated time points (24 weeks)
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C209). These data also appeared only in the US
FDA submission [17]. This study gave
bedaquiline to patients with newly diagnosed
or previously treated patients with either MDR-
TB or XDR-TB (where the isolate was sensitive to
at least three drugs other than bedaquiline).
Time to culture conversion at 24 weeks was the
primary outcome measure (Table 5) [17]. The
mean time to culture conversion was 57 days
[17]. A modified intention to treat analysis at
24 weeks showed that the rate of culture
conversion was 79.5%.
CLINICAL EVIDENCE FOR SAFETY
OF BEDAQUILINE
Pooled safety data are available from the first
and second Phase 2 studies [17]. Overall, 96.1%
of 102 subjects receiving bedaquiline and 95.2%
of the 105 subjects receiving placebo reported at
least one adverse event [17]. Adverse events
with a prevalence of more than 10% in the
pooled analysis of the first and second Phase 2
studies are presented in Table 6 [17, 62]. There
was no overall difference in the incidence of
these adverse events between groups, after
accounting for multiple testing. In the two
studies, 27.5% of subjects taking bedaquiline
and 22.9% of subjects taking placebo
experienced grade 3 or 4 adverse events of any
kind [17]. The most common of these events
was hyperuricemia, which occurred in 10.8% of
patients taking bedaquiline and 13.3% of
patients taking placebo.
The prevalence of drug-related hepatic
disorders was significantly higher in those
taking bedaquiline (8.8% in bedaquiline, 1.9%
in placebo, P = 0.03), with increases in alanine
transferase (ALT) observed in 5.0% of
bedaquline and in 1.0% of subjects taking
placebo [17]. Two patients taking bedaquiline
in the pooled Phase 2 studies had grade 3 or 4
liver function test abnormalities close to the
time of death [17]. The first death, attributed to
hepatitis and hepatic cirrhosis, occurred
approximately 3 months after the last
administered dose of the drug, but pre-
treatment transaminases and bilirubin were
normal, so it is possible the hepatic failure was
bedaquiline-related. A second patient died
513 days after the last dose of bedaquiline,
following liver failure and sepsis. Pretreatment
liver function was also normal in this patient,
and it is possible that the deterioration in liver
function was related to the drug.
Another patient developed liver injury after
taking bedaquiline, with more than a three-fold
increase in aspartate aminotransferase (AST)
and more than a two-fold increase in bilirubin.
It is possible that hepatotoxicity in this patient
was caused by bedaquiline; however,
concomitant alcoholic hepatitis and use of
other hepatotoxic anti-TB medications may
also explain the metabolic derangements [17].
Overall, the authors conclude that bedaquiline
was possibly responsible for serious liver
toxicity among patients in the Phase 2 studies
[16], and suggest careful monitoring,
particularly in patients with pre-existing liver
disease and/or regular alcohol use.
Acute pancreatitis occurred in two patients
taking bedaquiline, but no patients in the
placebo group. No events of rhabdomyolysis
or myopathy were reported.
Bedaquiline prolongs the corrected QT
interval (QTc). Close monitoring identified a
mean increase in QTc of 15.4 ms over the first
24 weeks for patients taking bedaquiline, and
7.7 ms among placebo patients in the first and
second studies [17]. The QTc was between
450 ms and 500 ms for 22.5% of patients
taking bedaquiline and 6.7% of patients taking
placebo in the first two studies. In the third
Infect Dis Ther (2013) 2:123–144 133
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Table 6 Adverse events of any grade, reported in at least 10% of subjects in the ﬁrst and second Phase 2 studies
Up to 24-week follow-up All follow-ups
In patients taking BDQ
for 24 weeksa
In patients taking





n5 79 n5 81 n5 102 n5 105
n (%) n (%) n (%) n (%)
Any adverse event 77 (97.5) 77 (95.1) 98 (96.1) 100 (95.2)
Gastrointestinal disorders 50 (63.3) 50 (61.7) 59 (57.8) 59 (56.2)
Nausea 30 (38.0) 26 (32.1) 36 (35.3) 27 (25.7)
Vomiting 20 (25.3) 21 (25.9) 21 (20.6) 24 (22.9)
Upper abdominal pain 9 (11.4) 7 (8.6) 10 (9.8) 8 (7.6)
Gastritis 6 (7.6) 13 (16.0) 6 (5.9) 13 (12.4)
Diarrhea 3 (3.8) 11 (13.6) 6 (5.9) 12 (11.4)
Nervous system disorders 32 (40.5) 21 (25.9) 37 (36.3) 24 (22.9)
Headache 22 (27.8) 10 (12.3) 24 (23.5) 12 (11.4)
Dizziness 10 (12.7) 10 (12.3) 13 (12.7) 12 (11.4)
Musculoskeletal disorders 35 (44.3) 32 (39.5) 41 (40.2) 39 (37.1)
Arthralgia 26 (32.9) 18 (22.2) 30 (29.4) 21 (20.0)
Ear and labyrinth
disorders
24 (30.4) 26 (32.1) 32 (31.4) 37 (35.2)
Deafness 9 (11.4) 6 (7.4) 12 (11.8) 11 (10.5)
Tinnitus 2 (2.5) 10 (12.3) 2 (2.0) 10 (9.5)
Respiratory disorders 25 (31.6) 28 (34.6) 28 (27.5) 33 (31.4)
Hemoptysis 14 (17.7) 9 (11.1) 17 (16.7) 13 (12.4)
Infections and
infestations
25 (31.6) 28 (34.6) 28 (27.5) 33 (31.4)
Chest pain 9 (11.4) 6 (7.4) 9 (8.8) 8 (7.6)
Skin and subcutaneous
tissues
19 (24.1) 21 (25.9) 25 (24.5) 28 (26.7)
Pruritis 10 (12.7) 11 (13.6) 12 (11.8) 13 (12.4)
Psychiatric disorders 15 (19.0) 11 (13.6) 16 (15.7) 13 (12.4)
Insomnia 11 (13.9) 9 (11.1) 11 (10.8) 10 (9.5)
Eye disorders 10 (12.7) 14 (17.3) 13 (12.7) 15 (14.3)
Blood and lymphatic
disorders
8 (10.1) 4 (4.9) 9 (8.8) 4 (3.8)
Reproductive system and
breast disorders
7 (8.9) 10 (12.3) 8 (7.8) 13 (12.4)
No signiﬁcant difference was identiﬁed for any of the listed adverse events, using Fisher’s exact test and correcting for
multiple testing using the Sidak correction [62]. Source: Modiﬁed from [17]
BDQ bedaquiline, OBR optimized background regimen
a 24 weeks: includes only subjects from the second phase 2 study (Study C208 [Stage 2]). This table includes pooled data
from the ﬁrst and second Phase 2 studies (Study C208 [Stage 1] and C208 [Stage 2])
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study, one patient taking bedaquiline had a QTc
exceeding 500 ms in and nine of 233 subjects
(3.9%) had an increase of over 60 ms. In a sub-
group analysis in the third study, at the end of
24 weeks, the mean increase in QTc was greater
for patients taking bedaquiline and clofazimine
(32-ms increase) than for bedaquiline alone
(12.3 ms) [17].
Increases in QTc generally occurred within
the first 8 weeks, stabilizing by 24 weeks in
pooled data from the two Phase 2 studies. No
episodes of Torsades de points (TdP) were
observed in any of the three studies to date,
although one death in the bedaquiline group
was due to myocardial infarction.
DEATHS
In the available studies, the mortality among
patients treated with bedaquiline was
significantly higher than with placebo. Pooled
analysis of the first two Phase 2 studies revealed
that 12 of 102 subjects (11.8%) died after taking
bedaquiline, while only four of 105 subjects
(3.8%) taking placebo died. Of the deaths in the
bedaquiline group, seven died during the trial
and five died after withdrawing prematurely. Of
the deaths in the placebo group, one died
during the trial and three died after
withdrawing prematurely. Deaths in the
bedaquiline group, for subjects in the first two
studies, occurred between 2 days and 911 days
(median 386 days) after the last dose. The
timing and cause of reported deaths from the
three studies are shown in Table 7. Three of the
12 deaths in the second Phase 2 study were
associated with grade 3 or grade 4 liver function
test abnormalities or liver-related adverse events
[15]. Deaths were not associated with any pre-
treatment characteristics.
In the third Phase 2 study, for which final
outcomes have not yet been reported, 16 of 233
subjects (6.9%) died prior to the cut-off time for
reporting to the US FDA. Of these deaths, four
were among individuals who had withdrawn
from the trial. Among those who attended
follow-up, deaths occurred between 12 days
and 685 days (median 376 days) after the last
bedaquiline dose [17].
These deaths were not considered by the
investigators to have been related to
bedaquiline, and the QTc was not C500 ms or
associated with a change of[60 ms from baseline.
There were also neither significant differences in
baseline characteristics nor electrocardiogram
(ECG) changes to explain the findings.
DISCUSSION
Effectiveness of Bedaquiline
It is premature to draw any conclusions
regarding the effectiveness of bedaquiline as
an adjunct to routine therapy for MDR-TB. The
paucity of published clinical data supports a
cautious approach to its use.
The primary end point in each of the three
studies was time to 2-month culture
conversion, a surrogate measure for
effectiveness. Two-month culture conversion
has been shown to predict non-relapsing cure
in clinical trials of drug-susceptible TB [63].
However, this biomarker has poor prognostic
value at the level of an individual patient [64]
and has not been validated for patients with
MDR-TB. Furthermore, the clinical importance
of reduced time to culture conversion is unclear,
as this may not necessarily correlate with
ultimate cure. The findings of efficacy at 8 and
24 weeks in Phase 2 studies must, therefore, be
interpreted with caution. Further controlled
trials with defined clinically significant end
points are required to confirm the findings of
the available data.
Infect Dis Ther (2013) 2:123–144 135
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Table 7 Summary of 28 deaths from the three Phase 2 studies (among 336 patients allocated to bedaquiline plus OBR, and


















1 2 Second BDQ No Converter Alcohol poisoning
2 12 Third BDQ ns Non-
converter
Renal impairment
3 27 Third BDQ ns Non-
converter
Tuberculosis
4 45 Third BDQ ns Non-
converter
Tuberculosis
5 71 Third BDQ ns Converter Lung infection
6 86 Second BDQ No Converter Hepatitis/hepatic
cirrhosis
7 105 Second Placebo No Non-
converter
Hemoptysis




9 262 Second BDQ Yes (non-compliance) Relapse Tuberculosis
10 262 Third BDQ ns Converter Congestive cardiac
failure





12 281 Second BDQ No Relapse Tuberculosis
13 288 Third BDQ ns Relapse Tuberculosis





15 344 Second BDQ No Relapse Tuberculosis





17 463 Third BDQ ns Non-
converter
Tuberculosis
18 473 Third BDQ ns Non-
converter
Hypertension




20 479 Third BDQ ns Converter Hemoptysis
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The available studies have a number of other
weaknesses. In the first Phase 2 study [17–19],
the reported rate of 8-week culture conversion
in the control population was surprisingly low
(only 8.7%), much less than that typically seen
with standard treatment of MDR-TB [5, 65]. This
raises concerns about the comparability of the
control group, although given the small study
population this may have occurred by chance.
The high rate of discontinuation from both
arms of this study is also concerning (54% in
placebo, 44% in bedaquiline groups by 2 years,
with half withdrawing within the first
6 months). This emphasizes the challenges of
MDR-TB treatment more generally.
The available evidence should be generalized
with caution beyond the patient population
involved in the available studies: patients with
smear microscopy positive for acid fast bacilli
with MDR-TB or pre-XDR-TB, aged between
18 years and 65 years. Until additional studies
are performed, the effectiveness of the drug to
treat MDR-TB in children or the elderly is
uncertain. The mean body mass index of
patients in the available studies was low, so
findings may also not apply to obese
populations. Further studies in this group are
particularly important,giventhe significant levels
of drug uptake into peripheral tissues, and its very
























22 513 Second BDQ No Converter Septic shock/
peritonitis
23 556 Second BDQ No Converter Cerebrovascular
accident
24 632 Third BDQ ns Converter Tuberculosis




26 709 Second Placebo Yes (non-compliance) Non-
converter
Tuberculosis
27 787 Second BDQ Yes (non-compliance) Non-
converter
Tuberculosis




Source: information from manufacturer’s submission to US FDA [17]. Data for mortality for incomplete trials are given up
to the reporting cut-off date speciﬁed in the manufacturer’s submission
BDQ bedaquiline, FDA US Food and Drugs Administration, ns not stated, OBR optimized background regimen, XDR-TB
extensively drug-resistant tuberculosis
a First study: Study C208 (Stage 1); Second study: Study C208 (Stage 2); Third study: Study C209
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women who are pregnant, or lactating, and
among patients with severe kidney disease or
severe hepatic impairment are also lacking.
Acquired Drug Resistance
with Bedaquiline
An important problem in the treatment of drug-
resistant TB is that inadequate anti-TB therapy
may lead to acquired drug resistance. Adding
bedaquiline may potentially reduce the
likelihood that more highly resistant isolates
will be selected. There are some data from the
available studies to support this supposition.
In the first Phase 2 study, five of 21 patients
(23.8%) with available baseline sensitivities
acquired additional second-line drug resistance
during the study, compared to one patient in
the bedaquiline group [19]. In the second Phase
2 study, two of 10 subjects (20%) taking
bedaquiline acquired resistance to one or more
additional drugs, compared to 14 of 27 (52%)
taking placebo [17]. However, the rate of
acquired drug resistance was substantially
higher in the third, uncontrolled, Phase 2
study, where 7 of 17 subjects taking
bedaquiline (41%) acquired additional drug
resistance [17]. The reason for the differences
in acquired resistance between the first two and
the third studies is not clear. However, it will be
important that proper monitoring for acquired
drug resistance is undertaken as bedaquiline is
used more widely.
Safety of Bedaquiline
The safety profile of bedaquiline requires
ongoing close scrutiny. Of particular concern,
there was a substantially higher mortality rate
among patients taking bedaquiline and OBRs
than those taking OBRs alone [17]. There is no
clear explanation for the difference in mortality
from the initial analyses. It is reassuring that
most deaths in the bedaquiline arm were
attributable to progression of TB, and did not
occur during bedaquiline therapy. Further, the
rate of mortality in the bedaquiline group was
close to the rate of 15% recently reported in a
meta-analysis of MDR-TB treatment outcomes
[5]. However, the significant mortality
difference between the bedaquiline group and
control group warrants careful ongoing
attention. For this reason, the US FDA has
applied a ‘Black Box’ warning to the drug.
The increased incidence of QT prolongation
among patients taking bedaquiline compared to
placebo raises important concerns about cardiac
toxicity of the drug. Prolongation of the QT
segment on a patient’s ECG, when corrected for
variability due to heart rate (QTc), reflects a
delay in cardiac repolarization that may be a
risk factor for a potentially fatal arrhythmia
called TdP. A mean QTc increase of 5 ms
compared to a placebo group is considered of
concern to regulators [66]. The mean increase
for bedaquiline was 7.7 ms [67]. In individual
patients, a measured QTc duration of more than
500 ms, or an increase of [60 ms, is considered
worrisome [67]. Despite no serious cardiac
arrhythmias being reported during or after
treatment in the available studies, the finding
does warrant careful monitoring of patients
taking the drug. In order to identify patients
at risk of TdP, baseline measurement QTc and
regular serial ECGs should be performed, as well
as serum potassium, calcium, and magnesium
at baseline. Patients should be carefully
selected, and the use of bedaquiline avoided if
the baseline QTc is [450 ms or if they have a
family history of heart failure. ECGs should be
repeated during treatment, and the drug should
be ceased immediately if the QT segment is
[500 ms or if a potentially fatal arrhythmia
occurs.
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Other drugs that prolong the QT segment may
amplify the risk of arrhythmias when used in
combination with bedaquiline [68]. However,
there is limited trial evidence evaluating the co-
administration of bedaquiline with other drugs.
A Phase 1 study showed increases in QTc with
ketoconazole and bedaquiline, and the third
Phase 2 study demonstrated higher QTc
duration in patients with clofazamine [17].
Consequently, caution is recommended when
using drugs that may prolong the QT interval.
Drugs that should be avoided with bedaquiline
include anti-arrhythmic drugs (such as class Ia/III
agents’ sotalol, dofetilide, and quinidine) and
several classes of antibiotics including
macrolides, imidazole anti-fungal cells, and
clofazimine. Fluoroquinolones have also been
associated with an increased incidence of serious
arrhythmias, with variation between different
agents. Recent studies have suggested that
arrhythmias may be more common for
moxifloxacin [69] and gatifloxacin [70] than
other quinolones; however, cardiac toxicity
appears to be a general class effect of quinolone
antibiotics. Consequently, careful cardiac
monitoring should be undertaken in further
studies where bedaquiline is given in
combination with any other agents that may
prolong the QT segment.
Liver function abnormalities were also more
common in the bedaquiline group, suggesting
that the drug must be used with great caution in
patients with liver disease. Although several of
the reported deaths in the studies involved liver
function test abnormalities, it was not certain
that bedaquiline caused these changes. Based
on current evidence, all patients’ liver function
tests should be monitored closely throughout
treatment, particularly when bedaquiline is co-
administered with other drugs associated with
liver toxicity (in particular pyrazinamide) [71].
The authors suggest that, as with first-line TB
drugs, the threshold of transaminases more
than five times the upper limit of normal, or
more than three times accompanied by
symptoms of liver toxicity, should lead to
immediate cessation of bedaquiline. In light of
the long half-life, monitoring should be
continued after cessation of the drug.
Considerable caution must also be exercised
when prescribing drugs that modulate the
enzyme CYP3A4 that primarily metabolizes
bedaquiline. Patients with MDR-TB often
receive drugs that act as CYP3A4 inhibitors
(such as protease inhibitors, macrolide
antibiotics, and some calcium channel
blockers) [72] or inducers (such as rifampicin,
efavirenz, nevirapine, glucocorticoids, and
some anti-convulsants). A range of
environmental, physiological, and genetic
factors may also influence CYP3A4 metabolism
[73]. Therefore, particular caution is needed for
patients being treated with bedaquiline,
particularly where other drugs are prescribed
for HIV co-infection, TB meningitis, and
treatment of other comorbidities.
The finding of drug-induced
phospholipidosis (DIP) in pre-clinical studies of
bedaquiline [19] may be relevant to some of the
drug’s observed toxicities. This process involves
the accumulation of phospholipids and the drug
within the lysosomes of any peripheral tissues,
such as the liver, lungs, and kidneys [74]. DIP
has been observed to occur for a number of other
cationic amphiphilic drugs commonly used in
clinical practice, including amiodarone,
azithromycin, gentamicin, sertraline, and
clozapine [67, 74]. For some drugs, such as
amiodarone and fluoxetine, DIP has been
associated with clinically relevant toxicity [67,
74]; however, there is ongoing debate whether
this is relevant to other drugs. The accumulation
of the drug in the tissues associated with DIP
may explain the long half-life of bedaquiline. In
Infect Dis Ther (2013) 2:123–144 139
123
animal studies of other drugs, the cellular
changes of DIP have been shown to be
reversible over weeks to months [74]; however,
the process remains poorly understood in
humans. It is possible that DIP explains the
observation that cardiac toxicity is more
pronounced in the patient sub-group taking
clofazimine [17], although this remains to be
confirmed. Until the relevance of DIP is better
understood with bedaquiline, caution should be
exercised when prescribing the drug with other
medications that are known to cause DIP.
Given the limitations of the current clinical
evidence, it is difficult to determine the risk-to-
benefit ratio for use of bedaquiline in treating
MDR-TB. Clearly, for patients with advanced
levels of drug resistance, the potential toxicities
may be justified. However, if effective
alternatives are available, bedaquiline should
be avoided until further data become available.
Programmatic Issues in the Use
of Bedaquiline
Given the importance of preserving effective
treatments for drug-resistant TB, bedaquiline
must be carefully protected so that drug
resistance does not become widespread.
Particularly in settings where MDR-TB and
XDR-TB are highly prevalent, the use of
bedaquiline must be carefully controlled. Off-
label use in the private sector should also be
avoided. Strong collaboration between the
pharmaceutical industry, government
regulators, National TB Programs, and other
stakeholders will be essential to minimize the
risk of drug resistance occurring. Appropriate
management of supply chain, monitoring of
compliance, and preventing off-label use will be
important in its effective implementation.
Routine programmatic monitoring and
reporting of adverse events must also be a
high priority. Outside of the carefully
controlled research setting, it will be essential
to inculcate a culture of careful monitoring for
adverse events into the training and evaluation
of staff. Monitoring for QT prolongation and
periodic liver function testing must be available
in all centers where this drug is deployed.
Future Directions for Research
There are many issues that remain to be clarified
regarding the use of bedaquiline. Further study
is needed to identify and develop optimal
regimens for treating patients with MDR-TB
using the drug. Patient eligibility must be
clearly articulated, and research is particularly
required among children, people living with
HIV, the obese, and the elderly. Further studies
examining the clinical significance of drug-
induced DIP must also be undertaken [75]. In
the future, the drug may also be considered in
drug susceptible disease, or for the treatment of
non-TB mycobacteria; however, there is
currently insufficient trial evidence in these
populations.
CONCLUSION
Bedaquline is a member of a novel class of anti-TB
drugs that has shown promise in early clinical
trials using surrogate end-points of efficacy. Before
its widespread use can be recommended, further
studies are required to evaluate the long-term
treatment outcomes, such as the rate of cure and
treatment failure and relapse after a full course of
MDR therapy. Careful evaluation of adverse events
is required as the drug is used more widely,
particularly monitoring for hepatotoxicity and
cardiotoxicity. Pharmacological interactions must
also be considered carefully. In light of the small
number of available studies, bedaquiline should
only be used in carefully monitored research
140 Infect Dis Ther (2013) 2:123–144
123
settings. While this new drug may become a
valuable player in the armamentarium used to
tackle drug-resistant TB, its risks and benefits must
first be better understood.
ACKNOWLEDGMENTS
This project was supported by the National
Health and Medical Research Council of
Australia, APP1054107. Dr Menzies is the
guarantor for this article, and takes
responsibility for the integrity of the work as a
whole.
Conflict of interest. Gregory J. Fox declares
no conflict of interest. Dick Menzies declares no
conflict of interest.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. World Health Organization. Global tuberculosis
control 2012. Geneva: 2012. http://www.who.int/
tb/publications/global_report/en/. Accessed on 1
May 2013.
2. World Health Organization. Treatment of
tuberculosis guidelines. Geneva: 2010. http://
www.who.int/tb/features_archive/new_treatment_
guidelines_may2010/en/index.html. Accessed on 1
May 2013.
3. Keshavjee S, Farmer PE. Tuberculosis, drug
resistance, and the history of modern medicine.
New Engl J Med. 2012;367:931–6.
4. World Health Organization. Guidelines for the
programmatic management of drug-resistant
tuberculosis. Geneva 2011. http://whqlibdoc.who.
int/publications/2011/9789241501583_eng.pdf.
Accessed on 1 May 2013.
5. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug
resistant pulmonary tuberculosis treatment
regimens and patient outcomes: an individual
patient data meta-analysis of 9,153 patients. PLoS
Med. 2012;9:e1001300.
6. Orenstein EW, Basu S, Shah NS, et al. Treatment
outcomes among patients with multidrug-resistant
tuberculosis: systematic review and meta-analysis.
Lancet Infect Dis. 2009;9:153–61.
7. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald
JM. Treatment outcomes of multidrug-resistant
tuberculosis: a systematic review and meta-
analysis. PLoS One. 2009;4:e6914.
8. Migliori GB, Sotgiu G, Gandhi NR, et al. The
collaborative group for meta-analysis of individual
patient data in MDR-TB. Drug resistance beyond
XDR-TB: results from a large individual patient data
meta-analysis. Eur Respir J. 2013;42:169–79.
9. The Stop TB Partnership. The Global Plan to Stop
TB 2011–2015. Geneva 2010. http://www.stoptb.
org/assets/documents/global/plan/TB_GlobalPlan
ToStopTB2011-2015.pdf. Accessed on 1 May 2013.
10. United States Food and Drug Administration. 2012.
http://www.fda.gov/NewsEvents/Newsroom/Press
Announcements/ucm333695.htm. Accessed on 1
May 2013.
11. World Health Organization. The use of bedaquiline
in the treatment of multidrug-resistant
tuberculosis. Interim policy guidance. http://www.
who.int/tb/challenges/mdr/bedaquiline/en/index.
html. Accessed on 1 May 2013.
12. Avorn J. Approval of a tuberculosis drug based
on a paradoxical surrogate measure. JAMA. 2013;
309:1349–50.
13. Cohen J. Infectious disease. Approval of novel TB
drug celebrated—with restraint. Science. 2013;339:
130.
14. Andries K, Verhasselt P, Guillemont J, et al. A
diarylquinoline drug active on the ATP synthase of
Mycobacterium tuberculosis. Science. 2005;307:
223–7.
15. US Food and Drug Administration. Briefing




on 1 May 2013.
16. Koul A, Vranckx L, Dendouga N, et al.
Diarylquinolines are bactericidal for dormant
mycobacteria as a result of disturbed ATP
homeostasis. J Biol Chem. 2008;283:25273–80.
Infect Dis Ther (2013) 2:123–144 141
123
17. Janssen Briefing Document. TMC207 (bedaquiline):
Treatment of patients with MDR-TB: NDA 204-384.




sed on 1 May 2013.
18. Diacon AH, Pym A, Grobusch M, et al. The
diarylquinoline TMC207 for multidrug-resistant
tuberculosis. N Engl J Med. 2009;360:
2397–405.
19. Diacon AH, Donald PR, Pym A, et al. Randomized
pilot trial of eight weeks of bedaquiline (TMC207)
treatment for multidrug-resistant tuberculosis:
long-term outcome, tolerability, and effect on
emergence of drug resistance. Antimicrob Agents
Chemother. 2012;56:3271–6.
20. Saga Y, Motoki R, Makino S, Shimizu Y, Kanai M,
Shibasaki M. Catalytic asymmetric synthesis of
R207910. J Am Chem Soc. 2010;132:7905–7.
21. Biukovic G, Basak S, Manimekalai MS, et al.
Variations of subunit varepsilon of the
Mycobacterium tuberculosis F1Fo ATP synthase and
a novel model for mechanism of action of the
tuberculosis drug TMC207. Antimicrob Agents
Chemother. 2013;57:168–76.
22. Haagsma AC, Podasca I, Koul A, et al. Probing the
interaction of the diarylquinoline TMC207 with its
target mycobacterial ATP synthase. PLoS One.
2011;6:e23575.
23. Guillemont J, Meyer C, Poncelet A, Bourdrez X,
Andries K. Diarylquinolines, synthesis pathways
and quantitative structure–activity relationship
studies leading to the discovery of TMC207.
Future Med Chem. 2011;3:1345–60.
24. Upadhayaya RS, Vandavasi JK, Kardile RA, et al.
Novel quinoline and naphthalene derivatives as
potent antimycobacterial agents. Eur J Med Chem.
2010;45:1854–67.
25. Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ,
et al. Selectivity of TMC207 towards mycobacterial
ATP synthase compared with that towards the
eukaryotic homologue. Antimicrob Agents
Chemother. 2009;53:1290–2.
26. Koul A, Dendouga N, Vergauwen K, et al.
Diarylquinolines target subunit c of mycobacterial
ATP synthase. Nat Chem Biol. 2007;3:323–4.
27. de Jonge MR, Koymans LH, Guillemont JE, Koul A,
Andries K. A computational model of the
inhibition of Mycobacterium tuberculosis ATPase by
a new drug candidate R207910. Proteins.
2007;67:971–80.
28. Petrella S, Cambau E, Chauffour A, Andries K, Jarlier
V, Sougakoff W. Genetic basis for natural and
acquired resistance to the diarylquinoline
R207910 in mycobacteria. Antimicrob Agents
Chemother. 2006;50:2853–6.
29. Gaurrand S, Desjardins S, Meyer C, et al.
Conformational analysis of r207910, a new drug
candidate for the treatment of tuberculosis, by a
combined NMR and molecular modeling approach.
Chem Biol Drug Des. 2006;68:77–84.
30. Segala E, Sougakoff W, Nevejans-Chauffour A,
Jarlier V, Petrella S. New mutations in the
mycobacterial ATP synthase: new insights into the
binding of the diarylquinoline TMC207 to the ATP
synthase C-ring structure. Antimicrob Agents
Chemother. 2012;56:2326–34.
31. Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S,
Andersson DI. Rates and mechanisms of resistance
development in Mycobacterium tuberculosis to a
novel diarylquinoline ATP synthase inhibitor.
Antimicrob Agents Chemother. 2010;54:1022–8.
32. Rouan MC, Lounis N, Gevers T, et al.
Pharmacokinetics and pharmacodynamics of
TMC207 and its N-desmethyl metabolite in a
murine model of tuberculosis. Antimicrob Agents
Chemother. 2012;56:1444–51.
33. Lounis N, Gevers T, Van Den Berg J, Andries K.
Impact of the interaction of R207910 with rifampin
on the treatment of tuberculosis studied in the
mouse model. Antimicrob Agents Chemother.
2008;52:3568–72.
34. Ibrahim M, Andries K, Lounis N, et al. Synergistic
activity of R207910 combined with pyrazinamide
against murine tuberculosis. Antimicrob Agents
Chemother. 2007;51:1011–5.
35. Zhang T, Li SY, Williams KN, Andries K,
Nuermberger EL. Short-course chemotherapy with
TMC207 and rifapentine in a murine model of
latent tuberculosis infection. Am J Respir Crit Care
Med. 2011;184:732–7.
36. Veziris N, Ibrahim M, Lounis N, Andries K, Jarlier V.
Sterilizing activity of second-line regimens
containing TMC207 in a murine model of
tuberculosis. PLoS One. 2011;6:e17556.
37. Tasneen R, Li SY, Peloquin CA, et al. Sterilizing
activity of novel TMC207- and PA-824-containing
regimens in a murine model of tuberculosis.
Antimicrob Agents Chemother. 2011;55:5485–92.
38. Shang S, Shanley CA, Caraway ML, et al. Activities
of TMC207, rifampin, and pyrazinamide against
Mycobacterium tuberculosis infection in guinea pigs.
Antimicrob Agents Chemother. 2011;55:124–31.
142 Infect Dis Ther (2013) 2:123–144
123
39. Andries K, Gevers T, Lounis N. Bactericidal
potencies of new regimens are not predictive of
their sterilizing potencies in a murine model of
tuberculosis. Antimicrob Agents Chemother.
2010;54:4540–4.
40. Veziris N, Ibrahim M, Lounis N, et al. A once-weekly
R207910-containing regimen exceeds activity of
the standard daily regimen in murine tuberculosis.
Am J Respir Crit Care Med. 2009;179:75–9.
41. IbrahimM,Truffot-PernotC,AndriesK, JarlierV,Veziris
N. Sterilizing activity of R207910 (TMC207)-containing
regimens in the murine model of tuberculosis. Am J
Respir Crit Care Med. 2009;180:553–7.
42. Lenaerts AJ, Hoff D, Aly S, et al. Location of
persisting mycobacteria in a Guinea pig model of
tuberculosis revealed by r207910. Antimicrob
Agents Chemother. 2007;51:3338–45.
43. Lounis N, Veziris N, Chauffour A, Truffot-Pernot C,
Andries K, Jarlier V. Combinations of R207910 with
drugs used to treat multidrug-resistant tuberculosis
have the potential to shorten treatment duration.
Antimicrob Agents Chemother. 2006;50:3543–7.
44. Upadhayaya RS, Lahore SV, Sayyed AY, Dixit SS,
Shinde PD, Chattopadhyaya J. Conformationally-
constrained indeno[2,1-c]quinolines—a new class
of anti-mycobacterial agents. Org Biomol Chem.
2010;8:2180–97.
45. Reddy VM, Einck L, Andries K, Nacy CA. In vitro
interactions between new antitubercular drug
candidates SQ109 and TMC207. Antimicrob
Agents Chemother. 2010;54:2840–6.
46. Diacon AH, Maritz JS, Venter A, et al. Time to
detection of the growth of Mycobacterium
tuberculosis in MGIT 960 for determining the early
bactericidal activity of antituberculosis agents. Eur J
Clin Microbiol Infect Dis. 2010;29:1561–5.
47. Dhillon J, Andries K, Phillips PP, Mitchison DA.
Bactericidal activity of the diarylquinoline TMC207
against Mycobacterium tuberculosis outside and
within cells. Tuberculosis. 2010;90:301–5.
48. Ji B, Lefrancois S, Robert J, Chauffour A, Truffot C,
Jarlier V. In vitro and in vivo activities of rifampin,
streptomycin, amikacin, moxifloxacin, R207910,
linezolid, and PA-824 against Mycobacterium ulcerans.
Antimicrob Agents Chemother. 2006;50:1921–6.
49. Sala C, Dhar N, Hartkoorn RC, et al. Simple model
for testing drugs against nonreplicating
Mycobacterium tuberculosis. Antimicrob Agents
Chemother. 2010;54:4150–8.
50. Upadhayaya RS, Vandavasi JK, Vasireddy NR,
Sharma V, Dixit SS, Chattopadhyaya J. Design,
synthesis, biological evaluation and molecular
modelling studies of novel quinoline derivatives
against Mycobacterium tuberculosis. Bioorg Med
Chem. 2009;17:2830–41.
51. Lounis N, Gevers T, Van den Berg J, Vranckx L,
Andries K. ATP synthase inhibition of
Mycobacterium avium is not bactericidal.
Antimicrob Agents Chemother. 2009;53:4927–9.
52. Gelber R, Andries K, Paredes RM, Andaya CE,
Burgos J. The diarylquinoline R207910 is
bactericidal against Mycobacterium leprae in mice at
low dose and administered intermittently.
Antimicrob Agents Chemother. 2009;53:3989–91.
53. Ji B, Chauffour A, Andries K, Jarlier V. Bactericidal
activities of R207910 and other newer antimicrobial
agents against Mycobacterium leprae in mice.
Antimicrob Agents Chemother. 2006;50:1558–60.
54. Huitric E, Verhasselt P, Andries K, Hoffner SE.
In vitro antimycobacterial spectrum of a
diarylquinoline ATP synthase inhibitor.
Antimicrob Agents Chemother. 2007;51:4202–4.
55. Rustomjee R, Diacon AH, Allen J, et al. Early
bactericidal activity and pharmacokinetics of the
diarylquinoline TMC207 in treatment of
pulmonary tuberculosis. Antimicrob Agents
Chemother. 2008;52:2831–5.
56. Diacon AH, Dawson R, Von Groote-Bidlingmaier F,
et al. Randomized dose-ranging study of the 14-day
early bactericidal activity of bedaquiline (TMC207)
in patients with sputum microscopy smear-positive
pulmonary tuberculosis. Antimicrob Agents
Chemother. 2013;57:2199–203.
57. Dooley KE, Park JG, Swindells S, ACTG 5267 Study
Team, et al. Safety, tolerability, and
pharmacokinetic interactions of the
antituberculous agent TMC207 (bedaquiline) with
efavirenz in healthy volunteers: AIDS Clinical Trials
Group Study A5267. J Acquir Immune Defic Syndr.
2012;59:455–62.
58. Svensson EM, Aweeka F, Park JG, Marzan F, Dooley
KE, Karlsson MO. Model-based estimates of the
effects of efavirenz on bedaquiline
pharmacokinetics and suggested dose adjustments
for patients co-infected with HIV and tuberculosis.
Antimicrob Agents Chemother. 2013;57:2780–7.
59. Wallis RS, Jakubiec W, Mitton-Fry M, et al. Rapid
evaluation in whole blood culture of regimens for
XDR-TB containing PNU-100480 (sutezolid),
TMC207, PA-824, SQ109, and pyrazinamide. PLoS
One. 2012;7:e30479.
60. Diacon AH, Dawson R, von Groote-Bidlingmaier F,
et al. 14-Day bactericidal activity of PA-824,
Infect Dis Ther (2013) 2:123–144 143
123
bedaquiline, pyrazinamide, and moxifloxacin
combinations: a randomised trial. Lancet.
2012;380:986–93.
61. Laserson KF, Thorpe LE, Leimane V, et al. Speaking
the same language: treatment outcome definitions
for multidrug-resistant tuberculosis. Int J Tuberc
Lung Dis. 2005;9:640–5.
62. Sidak Z. Confidence regions for the means of
multivariate normal distributions. J Am Stat Assoc.
1967;62:626–33.
63. Wallis RS, Pai M, Menzies D, et al. Biomarkers and
diagnostics for tuberculosis: progress, needs, and
translation into practice. Lancet. 2010;375:
1920–37.
64. Horne DJ, Royce SE, Gooze L, et al. Sputum
monitoring during tuberculosis treatment for
predicting outcome: systematic review and meta-
analysis. Lancet Infect Dis. 2010;10:387–94.
65. Gler MT, Skripconoka V, Sanchez-Garavito E, et al.
Delamanid for multidrug-resistant pulmonary
tuberculosis. N Engl J Med. 2012;366:2151–60.
66. Food and Drug Administration. E14 Clinical
evaluation of QT/QTc interval prolongation and
proarrhythmic potential for non-antiarrhythmic
drugs—questions and answers (R1). http://www.
fda.gov/Drugs/GuidanceComplianceRegulatory
Information/Guidances/ucm323656.htm. Accessed
on 28 May 2013.
67. Muehlbacher M, Tripal P, Roas F, Kornhuber J.
Identification of drugs inducing phospholipidosis
by novel in vitro data. Chem Med Chem. 2012;7:
1925–34.
68. Owens RC Jr, Nolin TD. Antimicrobial-associated
QT interval prolongation: pointes of interest. Clin
Infect Dis. 2006;43:1603–11.
69. Pugi A, Longo L, Bartoloni A, et al. Cardiovascular
and metabolic safety profiles of the
fluoroquinolones. Expert Opin Drug Saf. 2012;11:
53–69.
70. Lapi F, Wilchesky M, Kezouh A, Benisty JI, Ernst P,
Suissa S. Fluoroquinolones and the risk of serious
arrhythmia: a population-based study. Clin Infect
Dis. 2012;55:1457–65.
71. Shih TY, Pai CY, Yang P, Chang WL, Wang NC, Hu
OY. A novel mechanism underlies the
hepatotoxicity of pyrazinamide. Antimicrob
Agents Chemother. 2013;57:1685–90.
72. Zhou S, Chan E, Li X, Huang M. Clinical outcomes
and management of mechanism-based inhibition
of cytochrome P450 3A4. Ther Clin Risk Manag.
2005;1:3–13.
73. Klein K, Zanger UM. Pharmacogenomics of
cytochrome P450 3A4: recent progress toward the
‘‘Missing Heritability’’ problem. Front Genet.
2013;4:12.
74. Reasor MJ, Hastings KL, Ulrich RG. Drug-induced
phospholipidosis: issues and future directions.
Expert Opin Drug Saf. 2006;5:567–83.
75. Shayman JA, Abe A. Drug induced
phospholipidosis: an acquired lysosomal storage
disorder. Biochim Biophys Acta. 2013;1831:602–11.
144 Infect Dis Ther (2013) 2:123–144
123
